INSM - Insmed Incorporated News

The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome

Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliv

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension)

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full

Insmed Expands Community Impact During Fifth Annual Global Day of Good

Company-wide day of service brings together more than 1,350 employees to support over 50 organizatio

Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price t

Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Tr

Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity

Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels. BRINSUPRI's

Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized ba

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amik

— New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibr

If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized b

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make

Insmed to Present at September 2026 Investor Conferences

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first

fool.com

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New

Duquesne Family Office has beefed up its healthcare holdings.

Alger Mid Cap 40 ETF Q2 2026 Portfolio Review

The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatmen

— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosi

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the se

Biotech Is Booming, But These 2 Stocks Missed the Memo

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDA

Biotech Is Booming, But These 2 Stocks Missed the Memo

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree

JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the pri

Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises th

$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized ba

Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price tar

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and p

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169

Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises

Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and rai

marketbeat.com

Insmed Q2 Earnings Call Highlights

Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BR

S&P 500, Dow Fall as Brent Jumps 4%, SanDisk Trims Losses: Stock Market Today

Crude's rebound on Yemen strikes pulled U.S. equities off record highs Thursday, while SanDisk p

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Crude Oil Gains 2%; Keurig Dr Pepper Earnings Top Views

Dow drops over 300 points, NASDAQ down 0.05% and S&P 500 down 0.19%. Keurig Dr Pepper reports st

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the qua

Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Sto

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporti

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate

Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus

Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est

Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billio

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI ® (brensocatib)

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192

BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ:INSM) with a Outperform ra

Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning

Insmed reports 12-month TPIP extension data showing sustained efficacy and favorable safety in PAH a

Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reductio

–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures I

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161

Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises

Evercore ISI Group Maintains Outperform on Insmed, Lowers Price Target to $160

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and low

Why Is Nebius Stock Surging On Tuesday?

Nebius Group N.V. (NASDAQ: NBIS) stock surged on Tuesday after confirming its upcoming addition to t

CoreWeave, Astera Labs, Nebius Group, And Others Added To Nasdaq-100: A 'Big Deal,' Says Jim Cramer

CoreWeave, Astera Labs, Nebius, Rocket Lab & Teradyne join the Nasdaq-100. Jim Cramer calls this

Why Is CoreWeave Stock Soaring Friday?

CRWV stock climbs 5% as CoreWeave gears up to join the Nasdaq-100. Get the latest price action, incl

Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys